Overview
Bladder cancer ranks as the ninth most prevalent malignancy worldwide and takes the lead in the incidence of urinary system malignant tumors. This disease tends to affect the elderly population, with the peak onset age at 60, and men face a markedly higher risk of developing the disease than women. Characterized by high recurrence and progression rates, bladder cancer leads to distant tumor metastasis in nearly half of patients, which constitutes the primary cause of death among individuals with advanced bladder cancer. Tumor heterogeneity acts as the core contributor to inconsistent clinical therapeutic outcomes, and patients exhibit dramatically variable responses to standardized treatment regimens. Conventional tumor cell lines are derived from patients’ primary tumor tissues and can reflect the features of tumor gene mutations at the cellular level. Widely used bladder cancer cell lines such as T24, 5637 and J82 are easy to obtain and convenient to culture, yet they suffer from limited diversity of cell subtypes. During long-term serial passaging, cell lines are prone to phenotypic shift, making them incapable of accurately recapitulating the authentic pathological features of primary tumors and fully restoring the inherent heterogeneity of tumors. Patient-derived xenograft (PDX) models are established by implanting human tumor tissues into immunodeficient mice. These models can preserve the heterogeneity and complex biological traits of primary tumors to a certain extent, serving as favorable preclinical models for bladder cancer research. Nevertheless, PDX models have evident drawbacks: complicated operational procedures, excessive experimental costs, incompatibility with high-throughput drug screening, and the inability to simulate the regulatory effects of the human immune system on tumor growth and drug responses. Besides, the construction of PDX models for drug screening generally takes several months, resulting in extremely low experimental efficiency. Patient-derived bladder cancer organoids (BCa PDOs) represent an innovative and groundbreaking technical system in oncology research. They can faithfully recapitulate the tissue architecture and biological functions of human bladder cancer, offering an ideal research vehicle for individualized exploration of tumor heterogeneity, drug sensitivity and the mechanisms underlying drug resistance. Making up for the deficiencies of conventional experimental models, this system bridges the translational gap between basic research and clinical practice and provides novel support for the advancement of individualized precision medicine for bladder cancer.
Highlighted Products
Ucallm offers a comprehensive portfolio of antibodies with extensive target coverage. Its standard product line includes Rabbit mAbs, Mouse mAbs, Nanobodies, polyclonal antibodies and a full range of secondary antibodies. The featured specialty line consists of Biosimilar Antibodies, IVD-specific Antibodies, Functional Antibodies, Isotype Control Antibodies and more, fully catering to diverse experimental and R&D requirements. Ucallm implements rigorous quality control to ensure consistent and reliable performance across batches, delivering stable, hassle-free antibody solutions for research and industrial clients.
>> View productsComplete toolkit for in vitro cell research, covering organoids, cytokines, FBS, lab consumables and transfection reagents. Support stable cell culture, organoid modeling and cellular functional analysis to meet diverse experimental demands for life science studies.
>> View productsCore epigenomic protein-DNA interaction analysis technologies, covering gold-standard classic methods to cutting-edge low-input and single-cell chromatin profiling solutions, supporting scientific and clinical epigenetic research.
>> View productsBiomolecular interactions constitute the fundamental mechanisms sustaining life. Within cells, proteins rarely function in isolation; instead, they operate through dynamic and specific interaction networks with diverse biomolecules. These interactions encompass the assembly of functional protein complexes (protein-protein), the reading and regulation of genetic information (protein-DNA), post-transcriptional modification and transport (protein-RNA), signal transduction and metabolic regulation (protein-small molecule), and structural support and functional synergy with other macromolecules (protein-macromolecule). Elucidating the molecular mechanisms, spatiotemporal dynamics, and functional consequences of these interactions is essential for understanding cellular signaling pathways, disease pathogenesis, and drug target discovery.
>> View productsUcallm offers a full range of liquid handling consumables, including pipette tips, pipettes, reservoirs and storage bottles, to meet liquid handling requirements for various laboratory experiments
>> View productsAs a core branch of proteomics, modification proteomics enables systematic identification and quantification of protein post-translational modifications (PTMs). It analyzes dynamic variations in modification sites and modification abundance, and elucidates the regulatory mechanisms by which PTMs govern protein functions as well as cellular physiological and pathological processes. After proteins are translated by ribosomes, covalent chemical modifications can occur on their amino acid residues. Such modifications do not alter gene sequences yet greatly expand the functional diversity of proteins. Unlike conventional global proteomics, which only detects total protein expression levels, modification proteomics centers its research on diverse modification events.
>> View productsOrganoid models recapitulate a wide range of biological characteristics associated with human development, disease initiation, tissue homeostasis and tissue repair, yielding abundant promising candidate therapeutic targets. We supply a full portfolio of organoid research reagents alongside standardized culture systems, empowering cell biologists to refine culture protocols and establish organoid models featuring high viability as well as uniform and stable phenotypes.
>> View productsRecombinant proteins are manufactured using gene engineering techniques. Target genes are inserted into host cells—such as E. coli, mammalian, or insect cell systems—which then produce the desired proteins in large quantities. This technology has become indispensable to modern biomedical research, powering advances in drug discovery, diagnostic tools, vaccine development, and fundamental biology. At BioNEXT, our R&D team has developed one of the industry's broadest recombinant protein portfolios. With more than 20000 products in stock, we support research across immune checkpoint discovery, antibody drug development, CAR-T therapy, Fc receptor biology, influenza virology, and cytokine signaling. Every protein is manufactured under strict quality control, ensuring high purity and biological activity. Whether for biopharmaceutical target screening, structural biology, cell therapy, or enzyme characterization, BioNEXT offers reliable tools to accelerate your research.
>> View productsSample storage products include sentrifuge tubes ,cryogenic tubes and screw cap tubes.Multiple capacity specifications, suitable for various experimental scenarios.
>> View productsUnlock the 2-dimension and 3-dimension spatial biology — where molecules meet location, and data reveals life. We provide a complete spatial omics reagent ecosystem, empowering researchers to visualize, quantify, and decode the spatial architecture of tissues with unprecedented precision.
>> View productsTransfection is a key step in cell biology, gene expression, gene knockdown, and genome editing experiments. Transfection reagents cover both in vitro and in vivo applications, enabling efficient nucleic acid delivery across a wide variety of cell types, while the LNP-based platform achieves precise organ-selective targeting to the liver, spleen, and lungs. The reagents are ready-to-use without microfluidic equipment, seamlessly bridging in vitro mechanistic studies to in vivo efficacy validation for gene therapy and nucleic acid drug development.
>> View productsUcallm provides one-stop western blotting and protein analysis solutions.
>> View productsTry another keyword, SKU, CAS number, or product category.

